Between January 1988 and June 1992, 35 patients with primary anaplastic large cell lymphoma (ALCL)CD30+ were referred to one of the institutions participating in GISL (Gruppo Italiano per lo Studio dei Linformi). 16 patients were treated with ProMACE-CytaBOM, two with MACOP-B, one with CHOP and one with LSA(2)-L(2). As of November 1990, all newly diagnosed patients were treated with MOPP/EBV/CAD hybrid. 27 (77%) cases of ALCL CD30+ and 8 (23%) cases of Hodgkin's-related (HR) lymphoma CD30+ were diagnosed. Extranodal disease was present in 22 cases (63%), and 8 patients (23%) had primary bone marrow involvement. Twenty-three complete remissions (CR) (66%), six partial remissions (PR) (17%) and six no remissions (NR) (17%) were achieved with induction therapy. Results achieved with ProMACE-CytaBOM and MOPP/EBV/CAD hybrid were comparable. The overall response rate (CR+PR) was 85% for patients with classic ALCL CD30+ and 87% for those with HR lymphoma CD30+. The 3 year estimated overall survival rate was 66% and the 3 year relapse free survival rate was 65% for the entire group. The only significant favourable prognostic factor was the achievement of CR with initial therapy. Our findings suggest that ALCL (CD30+/Ki-1+) has a clinical outcome similar to aggressive non-Hodgkin's lymphoma (NHL). The use of an anthracycline-containing regimen will provide a change of cure in approximately 65% of cases.

ANAPLASTIC LARGE-CELL LYMPHOMA (CD30+/KI-1+) - ANALYSIS OF 35 CASES FOLLOWED AT GISL CENTERS / Longo, G; Federico, Massimo; Pieresca, C; Avanzini, P; Iannitto, E; Diprisco, Au; Baldini, L; Brugiatelli, M; Clo, V; Bevini, M; Silingardi, Vittorio. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - STAMPA. - 31:(1995), pp. 1763-1767. [10.1016/0959-8049(95)00318-D]

ANAPLASTIC LARGE-CELL LYMPHOMA (CD30+/KI-1+) - ANALYSIS OF 35 CASES FOLLOWED AT GISL CENTERS

FEDERICO, Massimo;SILINGARDI, Vittorio
1995

Abstract

Between January 1988 and June 1992, 35 patients with primary anaplastic large cell lymphoma (ALCL)CD30+ were referred to one of the institutions participating in GISL (Gruppo Italiano per lo Studio dei Linformi). 16 patients were treated with ProMACE-CytaBOM, two with MACOP-B, one with CHOP and one with LSA(2)-L(2). As of November 1990, all newly diagnosed patients were treated with MOPP/EBV/CAD hybrid. 27 (77%) cases of ALCL CD30+ and 8 (23%) cases of Hodgkin's-related (HR) lymphoma CD30+ were diagnosed. Extranodal disease was present in 22 cases (63%), and 8 patients (23%) had primary bone marrow involvement. Twenty-three complete remissions (CR) (66%), six partial remissions (PR) (17%) and six no remissions (NR) (17%) were achieved with induction therapy. Results achieved with ProMACE-CytaBOM and MOPP/EBV/CAD hybrid were comparable. The overall response rate (CR+PR) was 85% for patients with classic ALCL CD30+ and 87% for those with HR lymphoma CD30+. The 3 year estimated overall survival rate was 66% and the 3 year relapse free survival rate was 65% for the entire group. The only significant favourable prognostic factor was the achievement of CR with initial therapy. Our findings suggest that ALCL (CD30+/Ki-1+) has a clinical outcome similar to aggressive non-Hodgkin's lymphoma (NHL). The use of an anthracycline-containing regimen will provide a change of cure in approximately 65% of cases.
1995
31
1763
1767
ANAPLASTIC LARGE-CELL LYMPHOMA (CD30+/KI-1+) - ANALYSIS OF 35 CASES FOLLOWED AT GISL CENTERS / Longo, G; Federico, Massimo; Pieresca, C; Avanzini, P; Iannitto, E; Diprisco, Au; Baldini, L; Brugiatelli, M; Clo, V; Bevini, M; Silingardi, Vittorio. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - STAMPA. - 31:(1995), pp. 1763-1767. [10.1016/0959-8049(95)00318-D]
Longo, G; Federico, Massimo; Pieresca, C; Avanzini, P; Iannitto, E; Diprisco, Au; Baldini, L; Brugiatelli, M; Clo, V; Bevini, M; Silingardi, Vittorio
File in questo prodotto:
File Dimensione Formato  
Anaplastic large-cell.......pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 521.58 kB
Formato Adobe PDF
521.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/9863
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 13
social impact